2A Pharma ApS products

The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.

2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients. The Medical University of Vienna, Viral particles support prophylactic vaccination against breast cancer.

2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti-human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE vaccine is being investigated.

2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus. It is our hope that the drug candidate can be developed into a treatment for early-stage Alzheimer’s disease.

2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different partners.

Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines without knowing the antigen.